title: Etanercept and efalizumab treatment for high-need psoriasis. Effects and side effects in a prospective cohort study in outpatient clinical practice.
abstract: BACKGROUND
  Since the beginning of 2005, etanercept and efalizumab are officially registered and reimbursed for the treatment of recalcitrant psoriasis in The Netherlands.
  
  
  OBJECTIVE
  The evaluation of the efficacy, safety and adverse events of etanercept and efalizumab treatment in daily practice.
  
  
  METHODS
  A prospective cohort study was carried out for patients treated with etanercept or efalizumab between February 2005 and March 2006.
  
  
  RESULTS
  Over the past 13 months 45 individuals were treated with etanercept and 17 subjects were treated with efalizumab. The cohort represented a high-need population. At week 12, 82% of the subjects treated with 2 x 50 mg etanercept/week and 71% of the subjects treated with 2 x 25 mg etanercept/week reached a PASI-50. Efficacy of etanercept treatment was comparable to the results of clinical trials. For efalizumab, efficacy in responding patients was also comparable to clinical trial data, but the percentage of dropouts was substantial. During biologic treatment, safety was preserved and mainly mild adverse events were reported.
  
  
  CONCLUSIONS
  Etanercept and efalizumab are effective and safe treatments of psoriasis, even in a high-need population. Etanercept was able to sustain the clinical improvement throughout 24 weeks, whereas efalizumab was not in 47% of subjects.
authors.affiliation: Department of Dermatology, Radboud University Medical Centre, Nijmegen, The Netherlands. m.berends@derma.umcn.nl
authors.forename: Maartje A M
authors.initials: MA
authors.lastname: Berends
authors.forename: Rieke J B
authors.initials: RJ
authors.lastname: Driessen
authors.forename: Annechien M G
authors.initials: AM
authors.lastname: Langewouters
authors.forename: Jan B
authors.initials: JB
authors.lastname: Boezeman
authors.forename: Peter C M
authors.initials: PC
authors.lastname: Van De Kerkhof
authors.forename: Elke M G J
authors.initials: EM
authors.lastname: De Jong
mesh_terms: D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D015331:Cohort Studies; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D007155:Immunologic Factors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D007279:Injections, Subcutaneous; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011565:Psoriasis / Q000188:drug therapy* / Q000473:pathology; D018124:Receptors, Tumor Necrosis Factor / Q000008:administration & dosage / Q000627:therapeutic use*; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007074:Immunoglobulin G; D007155:Immunologic Factors; D018124:Receptors, Tumor Necrosis Factor; D000068800:Etanercept; C472181:efalizumab